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Abstract
Studies on in silico modeling and Xanthine oxidase (XO) inhibitory activities of Novel flavones derivatives with reference to gout

Hyperuricemia is a condition of defective purine metabolism characterized with elevated serum uric acid level (7 mg/dl) that further leads to Gout. One of the factors contributing to overproduction of uric acid is xanthine oxidase (XO) catalysis. XO is a complex metalloflavoprotein that catalyses the conversion of hypoxanthine to xanthine and xanthine to uric acid with concomitant production of hydrogen peroxide and super oxide anions.  Increase in uric acid level in serum eventually leads to the deposition of micro and macroscopic deposits of sodium hydrogen urate monohydrate crystals in the joints of humans that leads to the hyperuricemic condition called Gout. Deposition of urate crystals initiates an inflammatory reaction at the joints that includes swelling, redness and pain, the hallmark of inflammation. In addition a large amount of superoxide anion generation by XO has been involved in the pathogenesis of inflammation, mutagenesis, cancer, aging and ischemic reperfusion injury. Therefore XO inhibitors along with free radical scavengers may prove to be promising agents to treat Gout and hyperuricemic conditions and associated side effects. Purine analog Allopurinol is used as drug for inhibiting XO activity that blocks the synthesis of uric acid in Gout. Use of Allopurinol however is associated with adverse effects that include allergy, hypersensitivity reactions, gastrointestinal upset, skin rashes and acute interstitial nephritis due to lack of free radical scavenging activity against superoxide anions produced. Therefore there is a need for the development of novel compounds with better safety profiles that could be used to relieve associated side effects. Flavones are well known for their pharmacological activities including antitumor, antipyretic, anticancer, antioxidant, anti-inflammatory and XO inhibitory.
	Therefore present study was undertaken to synthesize some novel derivatives of flavones able to inhibit XO and scavenge the free radical produced.
As an attempt thiazolo derivatives V(a-z) and pyrazolo derivatives M(1-9) were designed using PASS, synthesized and characterized by using IR and NMR. In vitro evaluation of all synthesized derivatives for XO inhibitory and antioxidant activity was done using different assay conditions.  XO from rat was isolated and characterized for inhibitory assays having 17.2 U/mg of specific activity. Results in the form of IC50   values were recorded. Derivatives Vq, Vo, Vx, Vu, Vk, Vg, Vh, M6, M7 and Ve demonstrated satisfactory XO inhibitory and antioxidant activities in terms of IC50 values, in which Vq, Vo, Vh was more potent inhibitor. In silico docking studies were performed to have an insight of binding. In case of absence of 3D structure of XO, computational structure was constructed based on the homology with other sequence. Constructed model Model was validated using Verify 3D, Prosa and Ramchandran plot. Docking was done using BioMed Cache software. Results indicated presence of nonpolar amino acid in binding. Hydration number of binding of two most potent derivative Vq and Vo was derived using dielectric study using Time Domain Refractometer (TDR).  


